JAK2 and neoplasm: The studies of Severin et al. reported that the use of ibrutnib in combination with JAK2 and STAT3 inhibitors significantly increases the tumor cell death induced by ibrutinib, even in the presence of bone marrow mesenchymal stromal cells (BMSCs), which protect tumor cells from removal [33].